PortViewPortView
Bioventus logo

Bioventus (BVS) Stock Analysis

NASDAQHealthcareMedical - Devices

$14.27+4.41%
1-year price historyRange $6.51 – $15.26
52-week range$14.27
$6.26$15.89

What Bioventus does

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Key metrics

Market cap
$967.00M
P/E (TTM)
18.78
EPS (TTM)
$0.76
Beta
0.65
Dividend yield
0.00%
Revenue / share
$8.57
50-day avg
$12.59
200-day avg
$9.60
52-week high
$15.89
52-week low
$6.26
CEO
Robert Claypoole

ETFs linked to BVS

Broad-market and Healthcare sector ETFs an investor holding Bioventus is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BVS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze BVS in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Bioventus?
Bioventus trades under the ticker BVS on NASDAQ.
Which exchange is BVS listed on?
BVS is listed on NASDAQ.
What sector does Bioventus operate in?
Bioventus is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze BVS in a portfolio?
PortView shows BVS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.